Related Experiment Videos
Immunopharmacologic bases of immunotherapy
Clinical Physiology and Biochemistry
|January 1, 1985
Summary
Secondary immune deficiency, often seen in AIDS and cancer, can be treated with immunorestorative therapies. These therapies, including biologicals and drugs, improve host responses in immunocompromised individuals.
Area of Science:
- Immunology
- Pharmacology
Background:
- Secondary immune deficiency typically presents with more severe defects in cellular immunity compared to humoral immunity.
- Conditions like acquired immunodeficiency syndrome (AIDS), cancer, malnutrition, aging, and immunosuppressive therapy can lead to secondary immune deficiency.
Purpose of the Study:
- To review immunorestorative therapies for secondary immune deficiency.
- To discuss the safety and efficacy of biologicals and drugs in improving host responses, particularly in immunocompromised patients.
Main Methods:
- Review of biological therapies including thymic hormones and interferon.
- Analysis of chemically defined drugs such as levamisole, isoprinosine, azimexon, and muramyl dipeptides.
- Discussion of purine-related compounds to illustrate immunopharmacologic features.
Main Results:
- Immunorestorative therapies have demonstrated safety and efficacy in experimental use for cancer and other diseases.
- These therapies can enhance host responses, especially in immunocompromised individuals.
- Combined use of biologicals and drugs is suggested for enhanced immunotherapy efficiency.
Conclusions:
- Immunorestorative therapies offer a promising approach for managing secondary immune deficiencies.
- A combination of biologicals and drugs may optimize immunotherapy outcomes.